Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Aerosolized Nanoliposomal Carrier of Remdesivir: An Effective Alternative for COVID-19 Treatment In Vitro
Richa Vartak, Suyash M. Patil, Aishwarya Saraswat, et al.
Nanomedicine (2021) Vol. 16, Iss. 14, pp. 1187-1202
Open Access | Times Cited: 68

Showing 1-25 of 68 citing articles:

Micro and nano-carriers-based pulmonary drug delivery system: Their current updates, challenges, and limitations – A review
Mohit Kumar, Ayah Rebhi Hilles, Samah Hamed Almurisi, et al.
JCIS Open (2023) Vol. 12, pp. 100095-100095
Open Access | Times Cited: 37
The binding of heparin to spike glycoprotein inhibits SARS-CoV-2 infection by three mechanisms
Giulia Paiardi, Stefan Richter, Pasqua Oreste, et al.
Journal of Biological Chemistry (2021) Vol. 298, Iss. 2, pp. 101507-101507
Open Access | Times Cited: 72
Inhalation Delivery for the Treatment and Prevention of COVID-19 Infection
Basanth Babu Eedara, Wafaa Alabsi, David Encinas-Basurto, et al.
Pharmaceutics (2021) Vol. 13, Iss. 7, pp. 1077-1077
Open Access | Times Cited: 54
Nanomaterials for Photocatalytic Degradations of Analgesic, Mucolytic and Anti-Biotic/Viral/Inflammatory Drugs Widely Used in Controlling SARS-CoV-2
Mahsa Ebrahimi, Omid Akhavan
Catalysts (2022) Vol. 12, Iss. 6, pp. 667-667
Open Access | Times Cited: 53
Enhanced curcumin loaded nanocellulose: a possible inhalable nanotherapeutic to treat COVID-19
Thennakoon M. Sampath U. Gunathilake, Yern Chee Ching, Hiroshi Uyama, et al.
Cellulose (2022) Vol. 29, Iss. 3, pp. 1821-1840
Open Access | Times Cited: 45
Development of targeted nanoparticles loaded with antiviral drugs for SARS-CoV-2 inhibition
Vanna Sanna, Sandro Satta, Tzung K. Hsiai, et al.
European Journal of Medicinal Chemistry (2022) Vol. 231, pp. 114121-114121
Open Access | Times Cited: 43
Recent advances in nanoparticle applications in respiratory disorders: a review
Mohammad Ehsan Taghavizadeh Yazdi, Mohsen Qayoomian, Sima Beigoli, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 35
Intranasal liposomal remdesivir induces SARS-CoV-2 clearance in K18-hACE2 mice and ensures survival
Sabrina Mendes, Lays Cordeiro Guimarães, Leonardo Camilo de Oliveira, et al.
Journal of Controlled Release (2025) Vol. 379, pp. 558-573
Closed Access
Endolysosome-targeted nanoparticle delivery of antiviral therapy for coronavirus infections
Anton Petcherski, Brett M Tingley, Andrew Martin, et al.
Life Science Alliance (2025) Vol. 8, Iss. 4, pp. e202403182-e202403182
Open Access
Inhalable bedaquiline-loaded cubosomes for the treatment of non-small cell lung cancer (NSCLC)
Suyash M. Patil, Shruti S. Sawant, Nitesh K. Kunda
International Journal of Pharmaceutics (2021) Vol. 607, pp. 121046-121046
Closed Access | Times Cited: 50
Drug delivery challenges and formulation aspects of proteolysis targeting chimera (PROTACs)
Aishwarya Saraswat, Richa Vartak, Rehab Hegazy, et al.
Drug Discovery Today (2022) Vol. 28, Iss. 1, pp. 103387-103387
Open Access | Times Cited: 31
Advances in nanomedicine for the treatment of infectious diseases caused by viruses
Somya Ranjan Dash, Chanakya Nath Kundu
Biomaterials Science (2023) Vol. 11, Iss. 10, pp. 3431-3449
Closed Access | Times Cited: 18
Inhaled drug delivery: Past, present, and future
Ludan Yue, Xueyang Zhang, Chenchen Zhao, et al.
Nano Today (2023) Vol. 52, pp. 101942-101942
Closed Access | Times Cited: 15
A novel nanocomposite drug delivery system for SARS-CoV-2 infections
Uday Chintapula, Shazeed-Ul Karim, Priyanka Raghunathan Iyer, et al.
Nanoscale Advances (2024) Vol. 6, Iss. 15, pp. 3747-3758
Open Access | Times Cited: 5
Liposomal remdesivir inhalation solution for targeted lung delivery as a novel therapeutic approach for COVID-19
Jingjing Li, Kai Zhang, Di Wu, et al.
Asian Journal of Pharmaceutical Sciences (2021) Vol. 16, Iss. 6, pp. 772-783
Open Access | Times Cited: 37
Could Nanotechnology Help to End the Fight Against COVID-19? Review of Current Findings, Challenges and Future Perspectives
Ashagrachew Tewabe Yayehrad, Ebrahim Abdela Siraj, Gebremariam Birhanu Wondie, et al.
International Journal of Nanomedicine (2021) Vol. Volume 16, pp. 5713-5743
Open Access | Times Cited: 36
Susceptibility of Lung Carcinoma Cells to Nanostructured Lipid Carrier of ARV-825, a BRD4 Degrading Proteolysis Targeting Chimera
Richa Vartak, Aishwarya Saraswat, Yuqi Yang, et al.
Pharmaceutical Research (2022) Vol. 39, Iss. 11, pp. 2745-2759
Closed Access | Times Cited: 25
Antivirals and the Potential Benefits of Orally Inhaled Drug Administration in COVID-19 Treatment
Gokben Sahin, Özlem Akbal Dağıstan, Meltem Culha, et al.
Journal of Pharmaceutical Sciences (2022) Vol. 111, Iss. 10, pp. 2652-2661
Open Access | Times Cited: 25
Inhaled therapy for COVID-19: Considerations of drugs, formulations and devices
Tushar Saha, Miguel E. Quiñones‐Mateu, Shyamal C. Das
International Journal of Pharmaceutics (2022) Vol. 624, pp. 122042-122042
Open Access | Times Cited: 24
Pulmonary drug delivery: an effective and convenient delivery route to combat COVID-19
Shohreh Alipour, Laleh Mahmoudi, Fatemeh Ahmadi
Drug Delivery and Translational Research (2022) Vol. 13, Iss. 3, pp. 705-715
Open Access | Times Cited: 23
Recent Advances in Inhaled Nanoformulations of Vaccines and Therapeutics Targeting Respiratory Viral Infections
Ching-Yee Loo, Wing‐Hin Lee, Qi Zhou
Pharmaceutical Research (2023) Vol. 40, Iss. 5, pp. 1015-1036
Open Access | Times Cited: 12
Oral lipid nanocomplex of BRD4 PROteolysis TArgeting Chimera and vemurafenib for drug-resistant malignant melanoma
Aishwarya Saraswat, Richa Vartak, Rehab Hegazy, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 168, pp. 115754-115754
Open Access | Times Cited: 12
A quality-by-design strategic approach for the development of bedaquiline-pretomanid nanoparticles as inhalable dry powders for TB treatment
Suyash M. Patil, Alec M. Diorio, Parasharamulu Kommarajula, et al.
International Journal of Pharmaceutics (2024) Vol. 653, pp. 123920-123920
Closed Access | Times Cited: 3
Physicochemical Characteristics and In Vitro Toxicity/Anti-SARS-CoV-2 Activity of Favipiravir Solid Lipid Nanoparticles (SLNs)
Alaa S. Tulbah, Wing‐Hin Lee
Pharmaceuticals (2021) Vol. 14, Iss. 10, pp. 1059-1059
Open Access | Times Cited: 28
Pulmonary delivery of osimertinib liposomes for non-small cell lung cancer treatment: formulation development and in vitro evaluation
Shruti S. Sawant, Suyash M. Patil, Snehal K. Shukla, et al.
Drug Delivery and Translational Research (2021) Vol. 12, Iss. 10, pp. 2474-2487
Closed Access | Times Cited: 28
Page 1 - Next Page

Scroll to top